Alto Neuroscience, Inc. (ANRO)
$
14.61
+0.33 (2.26%)
Key metrics
Financial statements
Free cash flow per share
-2.0913
Market cap
405.1 Million
Price to sales ratio
1 Thousand
Debt to equity
0.0341
Current ratio
18.4335
Income quality
0.8493
Average inventory
0
ROE
-0.4481
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company focused on drug development in psychiatry. The company reported selling, general, and administrative expenses of $21,614,000.00 indicating its operational overhead costs. With total costs and expenses amounting to $68,610,000.00 the company reflects its overall spending. The EBITDA ratio is 0.00 highlighting the company's operational efficiency in managing its expenses against earnings. As it narrows its market focus, the company achieved a revenue of $0.00 illustrating its aim to cater to specific therapeutic needs. Furthermore, the company reported an income before tax of -$61,431,000.00 showcasing its pre-tax profitability as it works on developing treatments such as ALTO-100 for major depressive disorder (MDD) and post-traumatic stress disorder, ALTO-300, a melatonergic agonist and serotonergic antagonist, and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for cognitive impairment related to schizophrenia. Additionally, its innovative pipeline includes the development of ALTO-203, a histamine H3 receptor inverse agonist, and ALTO-202, an investigational antagonist of the GluN2B subunit of the NMDA receptor for MDD, alongside a unique AI-enabled biomarker platform. In the market context, the stock is affordable at $3.60 making it suitable for budget-conscious investors. The stock maintains an average trading volume of 1,642,071.00 indicating moderate liquidity for potential investors. With a market capitalization of $453,879,154.00 the company is classified as a small-cap player, which distinguishes it within the broader financial landscape. As a key player in the Biotechnology industry, Alto Neuroscience contributes significantly to the overall market landscape, showcasing its dedication to mental health advancements. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it seeks to address the complex challenges of psychiatric disorders through cutting-edge research and development.
Is Alto Neuroscience, Inc. (ANRO) a good investment?
Investing in Alto Neuroscience, Inc. (ANRO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Alto Neuroscience, Inc. (ANRO)'s stock forecast?
Analysts predict Alto Neuroscience, Inc. stock to fluctuate between $1.60 (low) and $16.49 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alto Neuroscience, Inc.'s market capitalization?
As of 2025-12-11, Alto Neuroscience, Inc.'s market cap is $453,879,154, based on 31,066,335 outstanding shares.
How does Alto Neuroscience, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alto Neuroscience, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alto Neuroscience, Inc. (ANRO) stock?
To buy Alto Neuroscience, Inc. (ANRO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANRO. Place an order (Market, Limit, etc.).
What is the best time to invest in Alto Neuroscience, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alto Neuroscience, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.50 | Growth: 85.19%.
Where can I find Alto Neuroscience, Inc.'s investor relations reports?
Visit https://www.altoneuroscience.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alto Neuroscience, Inc.?
You can explore historical data from here
What is the all-time high and low for Alto Neuroscience, Inc. stock?
All-time high: $24 (2024-02-05) | All-time low: $1.60 (2025-04-04).
What are the key trends affecting Alto Neuroscience, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Here is how Alto Neuroscience, Inc. (ANRO) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
zacks.com
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
businesswire.com
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 1.
businesswire.com
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $50 million, before deducting offering expenses. The financing.
globenewswire.com
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of Alto Neuroscience, Inc. (NYSE: ANRO) shareholders against certain of its officers and directors who may have breached the fiduciary duties they owed to the Company.
prnewswire.com
SAN DIEGO , Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering ("IPO") conducted on or about February 2, 2024, and/or (b) Alto securities between February 2, 2024 and October 22, 2024.
globenewswire.com
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.
globenewswire.com
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline.
prnewswire.com
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
See all news
